Alteplase for ischaemic stroke - Responses

The Lancet

Volumn 384, Issue 9944, 2014, Pages 662-663

  Hudson, Ian ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BRAIN ISCHEMIA; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; EUROPEAN; HUMAN; LETTER; META ANALYSIS (TOPIC); NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84906713592     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61388-X     Document Type: Letter

References (4)

1. The IST-3 collaborative group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (IST-3): a randomised controlled trial Lancet 379 2012 2352 2363
2. The IST-3 collaborative group Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial Lancet Neurol 12 2013 768 776
3. M O'Fallon, K Asplund, LR Goldfrank et al. Report of the t-PA Review Committee http://stroke.nih.gov/resources/t-pa-review-committee.htm 2004 (accessed July 31, 2014).
4. J Emberson, KR Lees, P Lyden et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials Lancet 2014 10.1016/S0140-6736(14)60584-5 published online Aug 6